文献速递其他结缔组织病

利奥西呱治疗早期弥漫性皮肤型系统性硬化症2b期随机安慰剂对照试验的生物标志物分析

Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

第14周时利奥西呱组血浆cGMP较基线升高94(78)%,安慰剂组升高10(39)%(P<0.001);利奥西呱组血清sPECAM-1和CXCL-4较安慰剂组降低(P=0.004和P=0.008)。基线sPECAM-1较高或基线皮肤活检αSMA阳性细胞与第52周改良Rodnan皮肤评分更大降幅相关。

要点

  • 利奥西呱组第14周血浆cGMP较基线升高94(78)%,安慰剂组升高10(39)%(P<0.001)。
  • 利奥西呱组血清sPECAM-1和CXCL-4较安慰剂组降低(P=0.004和P=0.008)。
  • 基线sPECAM-1较高或αSMA阳性皮肤细胞与第52周mRSS更大降幅相关(交互P=0.004和0.02)。

核心结论

  • 血浆cGMP随利奥西呱治疗升高,提示药物与一氧化氮-可溶性鸟苷酸环化酶-cGMP通路结合。
  • 利奥西呱与安慰剂相比与sPECAM-1(一种血管生成生物标志物)显著降低相关。
  • 基线sPECAM-1升高和皮肤αSMA阳性细胞可能有助于识别在皮肤纤维化方面可能从利奥西呱获益的患者。

研究设计与样本

  • RISE-SSc为2b期随机安慰剂对照试验,患者随机接受利奥西呱(n=60)或安慰剂(n=61)治疗52周。
  • 基线和第14周获取皮肤活检及血浆/血清样本,采用放射免疫分析法检测血浆cGMP。
  • 通过免疫组化测定αSMA和皮肤厚度,通过qRT-PCR检测皮肤活检纤维化mRNA标志物,通过酶联免疫吸附试验检测血清CXCL-4和sPECAM-1。

主要发现

  • 第14周时,利奥西呱组cGMP较基线升高94(78)%,安慰剂组升高10(39)%(P<0.001,利奥西呱 vs 安慰剂)。
  • 利奥西呱组较安慰剂组血清sPECAM-1和CXCL-4降低(P=0.004和P=0.008)。
  • 两组间皮肤胶原标志物无差异。
  • 基线血清sPECAM-1较高或基线皮肤活检检出αSMA阳性细胞与利奥西呱组较安慰剂组第52周mRSS较基线更大降幅相关(交互P值分别为0.004和0.02)。

关键数值与推荐

  • 第14周cGMP变化:利奥西呱组升高94(78)%,安慰剂组升高10(39)%,P<0.001。
  • 血清sPECAM-1组间比较P=0.004,CXCL-4组间比较P=0.008,均为利奥西呱组较安慰剂组降低。
  • 基线sPECAM-1与第52周mRSS降幅交互P=0.004,基线αSMA阳性细胞与第52周mRSS降幅交互P=0.02。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine disease and target engagement biomarkers in the RISE-SSc trial of riociguat in early diffuse cutaneous systemic sclerosis and their potential to predict the response to treatment. METHODS: Patients were randomized to riociguat (n = 60) or placebo (n = 61) for 52 weeks. Skin biopsies and plasma/serum samples were obtained at baseline and week 14. Plasma cyclic guanosine monophosphate (cGMP) was assessed using radio-immunoassay. α-Smooth muscle actin (αSMA) and skin thickness were determined by immunohistochemistry, mRNA markers of fibrosis by qRT-PCR in skin biopsies, and serum CXC motif chemokine ligand 4 (CXCL-4) and soluble platelet endothelial cell adhesion molecule-1 (sPECAM-1) by enzyme-linked immunosorbent assay. RESULTS: By week 14, cGMP increased by 94 (78)% with riociguat and 10 (39)% with placebo (P < 0.001, riociguat vs placebo). Serum sPECAM-1 and CXCL-4 decreased with riociguat vs placebo (P = 0.004 and P = 0.008, respectively). There were no differences in skin collagen markers between the two groups. Higher baseline serum sPECAM-1 or the detection of αSMA-positive cells in baseline skin biopsies was associated with a larger reduction of modified Rodnan skin score from baseline at week 52 with riociguat vs placebo (interaction P-values 0.004 and 0.02, respectively). CONCLUSION: Plasma cGMP increased with riociguat, suggesting engagement with the nitric oxide-soluble guanylate cyclase-cGMP pathway. Riociguat was associated with a significant reduction in sPECAM-1 (an angiogenic biomarker) vs placebo. Elevated sPECAM-1 and the presence of αSMA-positive skin cells may help to identify patients who could benefit from riociguat in terms of skin fibrosis. TRIAL REGISTRATION: Clinicaltrials.gov, NCT02283762.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Khanna D, Kramer F, Höfler J, et al. Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis. Rheumatology (Oxford). 2024. PMID: 38460548. doi:10.1093/rheumatology/keae150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。